The phase I clinical trial mainly showed the long-term follow-up outcomes of relapsed B-ALL patients who received CD19-CAR-T cell therapy and evaluated the safety of this therapy (56). This evidence concerns the gene CD19 and precursor B-cell acute lymphoblastic leukemia.